Annual CFO
-$5.21 M
+$4.62 M+47.00%
31 December 2022
Summary:
Nymox Pharmaceutical annual cash flow from operations is currently -$5.21 million, with the most recent change of +$4.62 million (+47.00%) on 31 December 2022. During the last 3 years, it has risen by +$4.83 million (+48.14%).NYMX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$988.00 K
+$261.00 K+20.90%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly cash flow from operations is currently -$988.00 thousand, with the most recent change of +$261.00 thousand (+20.90%) on 31 March 2023.NYMX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$1.99 M
+$3.22 M+61.84%
31 March 2023
Summary:
Nymox Pharmaceutical TTM cash flow from operations is currently -$1.99 million, with the most recent change of +$3.22 million (+61.84%) on 31 March 2023.NYMX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +48.1% | +67.1% | +78.5% |
| 5 y5 years | +33.3% | +47.8% | +72.8% |
NYMX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -166.2% | -108.4% | -125.3% |
Nymox Pharmaceutical Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$988.00 K(-20.9%) | -$1.99 M(-61.8%) |
| Dec 2022 | -$5.21 M(-47.0%) | -$1.25 M(-4.4%) | -$5.21 M(-16.1%) |
| Sept 2022 | - | -$1.31 M(-183.9%) | -$6.21 M(-21.4%) |
| June 2022 | - | $1.56 M(-137.0%) | -$7.90 M(-30.5%) |
| Mar 2022 | - | -$4.21 M(+87.1%) | -$11.36 M(+15.7%) |
| Dec 2021 | -$9.82 M(-2.2%) | -$2.25 M(-25.0%) | -$9.82 M(+6.1%) |
| Sept 2021 | - | -$3.00 M(+57.7%) | -$9.26 M(-9.9%) |
| June 2021 | - | -$1.90 M(-28.7%) | -$10.28 M(-2.5%) |
| Mar 2021 | - | -$2.67 M(+58.5%) | -$10.54 M(+5.0%) |
| Dec 2020 | -$10.04 M(+35.1%) | -$1.68 M(-58.1%) | -$10.04 M(-1.3%) |
| Sept 2020 | - | -$4.02 M(+85.8%) | -$10.17 M(+26.5%) |
| June 2020 | - | -$2.16 M(-0.2%) | -$8.04 M(+0.4%) |
| Mar 2020 | - | -$2.17 M(+19.6%) | -$8.01 M(+7.8%) |
| Dec 2019 | -$7.43 M(-4.8%) | -$1.81 M(-4.2%) | -$7.43 M(+1.7%) |
| Sept 2019 | - | -$1.89 M(-11.3%) | -$7.30 M(-6.2%) |
| June 2019 | - | -$2.13 M(+33.8%) | -$7.78 M(+2.9%) |
| Mar 2019 | - | -$1.59 M(-5.6%) | -$7.56 M(-3.1%) |
| Dec 2018 | -$7.80 M(+25.7%) | -$1.69 M(-28.8%) | -$7.80 M(+5.7%) |
| Sept 2018 | - | -$2.37 M(+24.1%) | -$7.38 M(-0.8%) |
| June 2018 | - | -$1.91 M(+4.2%) | -$7.44 M(+1.9%) |
| Mar 2018 | - | -$1.83 M(+44.4%) | -$7.30 M(+17.6%) |
| Dec 2017 | -$6.21 M(+37.8%) | -$1.27 M(-47.7%) | -$6.21 M(-3.9%) |
| Sept 2017 | - | -$2.43 M(+37.3%) | -$6.45 M(+37.9%) |
| June 2017 | - | -$1.77 M(+139.1%) | -$4.68 M(+30.0%) |
| Mar 2017 | - | -$740.00 K(-51.2%) | -$3.60 M(-20.1%) |
| Dec 2016 | -$4.50 M(+20.0%) | -$1.52 M(+132.3%) | -$4.50 M(+6.3%) |
| Sept 2016 | - | -$653.30 K(-5.0%) | -$4.24 M(-11.1%) |
| June 2016 | - | -$687.60 K(-58.2%) | -$4.76 M(-4.4%) |
| Mar 2016 | - | -$1.64 M(+31.3%) | -$4.99 M(+32.8%) |
| Dec 2015 | -$3.75 M(-32.0%) | -$1.25 M(+5.9%) | -$3.75 M(+3.5%) |
| Sept 2015 | - | -$1.18 M(+30.1%) | -$3.62 M(-10.2%) |
| June 2015 | - | -$908.20 K(+121.0%) | -$4.04 M(-11.0%) |
| Mar 2015 | - | -$411.00 K(-63.4%) | -$4.54 M(-17.8%) |
| Dec 2014 | -$5.52 M(-17.9%) | -$1.12 M(-29.6%) | -$5.52 M(-6.3%) |
| Sept 2014 | - | -$1.60 M(+13.6%) | -$5.89 M(-5.5%) |
| June 2014 | - | -$1.40 M(+1.0%) | -$6.23 M(-3.5%) |
| Mar 2014 | - | -$1.39 M(-6.9%) | -$6.46 M(-3.8%) |
| Dec 2013 | -$6.72 M(-19.1%) | -$1.50 M(-22.9%) | -$6.72 M(-6.5%) |
| Sept 2013 | - | -$1.94 M(+19.0%) | -$7.18 M(+4.2%) |
| June 2013 | - | -$1.63 M(-1.0%) | -$6.90 M(-5.1%) |
| Mar 2013 | - | -$1.65 M(-16.1%) | -$7.26 M(-12.5%) |
| Dec 2012 | -$8.30 M(-18.1%) | -$1.96 M(+18.8%) | -$8.30 M(+0.9%) |
| Sept 2012 | - | -$1.65 M(-17.3%) | -$8.23 M(-4.6%) |
| June 2012 | - | -$2.00 M(-25.7%) | -$8.63 M(-4.1%) |
| Mar 2012 | - | -$2.69 M(+42.1%) | -$9.00 M(-11.2%) |
| Dec 2011 | -$10.14 M(-229.0%) | -$1.89 M(-7.6%) | -$10.14 M(-390.5%) |
| Sept 2011 | - | -$2.05 M(-13.5%) | $3.49 M(-17.8%) |
| June 2011 | - | -$2.37 M(-38.1%) | $4.25 M(-21.8%) |
| Mar 2011 | - | -$3.83 M(-132.6%) | $5.44 M(-30.8%) |
| Dec 2010 | $7.86 M | $11.74 M(-1009.5%) | $7.86 M(-261.6%) |
| Sept 2010 | - | -$1.29 M(+9.2%) | -$4.86 M(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | -$1.18 M(-15.8%) | -$4.62 M(+7.4%) |
| Mar 2010 | - | -$1.40 M(+41.9%) | -$4.30 M(+22.6%) |
| Dec 2009 | -$3.50 M(+0.3%) | -$988.80 K(-5.3%) | -$3.50 M(-0.3%) |
| Sept 2009 | - | -$1.04 M(+21.0%) | -$3.52 M(+5.1%) |
| June 2009 | - | -$862.60 K(+41.5%) | -$3.35 M(+8.5%) |
| Mar 2009 | - | -$609.60 K(-39.1%) | -$3.08 M(-11.8%) |
| Dec 2008 | -$3.50 M(-5.2%) | -$1.00 M(+14.6%) | -$3.50 M(+12.9%) |
| Sept 2008 | - | -$873.40 K(+45.6%) | -$3.10 M(+1.9%) |
| June 2008 | - | -$600.00 K(-41.3%) | -$3.04 M(-21.1%) |
| Mar 2008 | - | -$1.02 M(+70.2%) | -$3.85 M(+4.4%) |
| Dec 2007 | -$3.69 M(-12.5%) | -$600.30 K(-26.5%) | -$3.69 M(-12.6%) |
| Sept 2007 | - | -$817.10 K(-42.1%) | -$4.22 M(+7.9%) |
| June 2007 | - | -$1.41 M(+64.5%) | -$3.91 M(-7.2%) |
| Mar 2007 | - | -$858.20 K(-24.3%) | -$4.21 M(-0.0%) |
| Dec 2006 | -$4.21 M(+66.7%) | -$1.13 M(+123.7%) | -$4.21 M(+14.2%) |
| Sept 2006 | - | -$506.50 K(-70.5%) | -$3.69 M(-5.7%) |
| June 2006 | - | -$1.72 M(+99.9%) | -$3.91 M(+41.9%) |
| Mar 2006 | - | -$858.40 K(+40.8%) | -$2.76 M(+9.1%) |
| Dec 2005 | -$2.53 M(-21.8%) | -$609.60 K(-16.5%) | -$2.53 M(-9.9%) |
| Sept 2005 | - | -$729.90 K(+30.1%) | -$2.81 M(-3.4%) |
| June 2005 | - | -$561.00 K(-10.7%) | -$2.90 M(+6.8%) |
| Mar 2005 | - | -$628.10 K(-29.3%) | -$2.72 M(-15.8%) |
| Dec 2004 | -$3.23 M(-10.0%) | -$887.80 K(+7.2%) | -$3.23 M(-2.5%) |
| Sept 2004 | - | -$827.80 K(+119.6%) | -$3.31 M(+9.5%) |
| June 2004 | - | -$376.90 K(-67.0%) | -$3.03 M(-15.5%) |
| Mar 2004 | - | -$1.14 M(+17.6%) | -$3.58 M(-0.2%) |
| Dec 2003 | -$3.59 M(+49.2%) | -$969.60 K(+79.1%) | -$3.59 M(+16.8%) |
| Sept 2003 | - | -$541.30 K(-41.8%) | -$3.07 M(-5.3%) |
| June 2003 | - | -$930.70 K(-19.0%) | -$3.25 M(+8.1%) |
| Mar 2003 | - | -$1.15 M(+153.0%) | -$3.00 M(+24.8%) |
| Dec 2002 | -$2.41 M(-7.3%) | -$454.00 K(-36.4%) | -$2.41 M(-10.6%) |
| Sept 2002 | - | -$713.80 K(+3.8%) | -$2.69 M(+2.4%) |
| June 2002 | - | -$687.90 K(+24.9%) | -$2.63 M(+5.7%) |
| Mar 2002 | - | -$550.90 K(-25.4%) | -$2.49 M(-4.1%) |
| Dec 2001 | -$2.60 M(-32.8%) | -$738.80 K(+13.5%) | -$2.60 M(-1.2%) |
| Sept 2001 | - | -$651.10 K(+19.0%) | -$2.63 M(-13.4%) |
| June 2001 | - | -$547.30 K(-16.8%) | -$3.03 M(-16.4%) |
| Mar 2001 | - | -$658.00 K(-14.4%) | -$3.62 M(-6.1%) |
| Dec 2000 | -$3.86 M(+46.1%) | -$769.00 K(-27.2%) | -$3.86 M(+12.4%) |
| Sept 2000 | - | -$1.06 M(-7.5%) | -$3.43 M(+4.6%) |
| June 2000 | - | -$1.14 M(+27.8%) | -$3.28 M(+15.8%) |
| Mar 2000 | - | -$893.10 K(+160.6%) | -$2.83 M(+7.3%) |
| Dec 1999 | -$2.64 M(-47.5%) | -$342.70 K(-62.1%) | -$2.64 M(-29.0%) |
| Sept 1999 | - | -$905.20 K(+30.7%) | -$3.72 M(-7.5%) |
| June 1999 | - | -$692.70 K(-1.1%) | -$4.02 M(+5.0%) |
| Mar 1999 | - | -$700.20 K(-50.8%) | -$3.83 M(-23.8%) |
| Dec 1998 | -$5.03 M(+48.1%) | -$1.42 M(+17.8%) | -$5.03 M(+39.4%) |
| Sept 1998 | - | -$1.21 M(+140.1%) | -$3.61 M(+50.3%) |
| June 1998 | - | -$502.80 K(-73.5%) | -$2.40 M(+26.5%) |
| Mar 1998 | - | -$1.90 M | -$1.90 M |
| Dec 1997 | -$3.40 M | - | - |
FAQ
- What is Nymox Pharmaceutical annual cash flow from operations?
- What is the all time high annual CFO for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly cash flow from operations?
- What is the all time high quarterly CFO for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical TTM cash flow from operations?
- What is the all time high TTM CFO for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual cash flow from operations?
The current annual CFO of NYMX is -$5.21 M
What is the all time high annual CFO for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual cash flow from operations is $7.86 M
What is Nymox Pharmaceutical quarterly cash flow from operations?
The current quarterly CFO of NYMX is -$988.00 K
What is the all time high quarterly CFO for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly cash flow from operations is $11.74 M
What is Nymox Pharmaceutical TTM cash flow from operations?
The current TTM CFO of NYMX is -$1.99 M
What is the all time high TTM CFO for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high TTM cash flow from operations is $7.86 M